pharmaphorum

MARCH 19, 2021

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . The post Digitalising drug discovery appeared first on.

Bioinformatics 59

Bioinformatics Drugs Genome Genomics 59

XTalks

APRIL 15, 2021

Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. However, these drugs have shown limited effectiveness in treating HFpEF. Case Study: Genomic Approaches in Coronary Artery Disease Drug Development.

Development 98

Development Drugs Genome Genomics 98

pharmaphorum

DECEMBER 2, 2021

It will focus its efforts initially on neurological diseases like Alzheimer’s and Parkinson’s, using technologies that can measure how disease alters tissues, cells and proteins, with the aim of increasing the success rate of drug discovery and development. Milestone payments tied to progress of the two drugs could add another $1.5

Biobanking 93

Biobanking Genome Genomics Genetics 93

The Pharma Data

MARCH 1, 2022

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd. More information at www.lifebit.ai.

Biobanking 52

Biobanking Genome Genomics Genome Project 52

pharmaphorum

JANUARY 26, 2023

Understanding individual drug reactions and metabolism Pharmacogenomics is emerging as an important area. Genomic insights will increasingly be used to reduce the hundreds of millions of pounds wasted administering drugs that are ineffective due to an individual’s genetic makeup.

Genome 129

Genome Genomics Genome Project Genetics 129

The Pharma Data

JULY 8, 2021

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). These genetic data have been paired with detailed health information to create this browsable resource.

Genetics 52

Genetics Biobanking Protein Containment 52

The Pharma Data

JULY 12, 2021

online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. the success rates in drug discovery?are HUMANOID Center of Research Excellence?(CoRE),

Drugs 52

Drugs Gene Expression Big Data Gene 52

The Pharma Data

AUGUST 30, 2021

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. MADRID-COVID is a randomized clinical trial conducted in close collaboration between the CNIC and cardiology, ICU, pulmonology, and biobank services at FJD Hospital.

Drugs 52

Drugs Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

“You might not see it immediately because many of these larger companies happen to also have their own internal biobanks, so they are not entirely reliant on primary acquisition of samples on the outside,” Ianelli said. I think it’s also important to think about the definition of biobanks. These are banks.

Research 52

Research Biobanking Clinical Trials Clinical Trials 52

pharmaphorum

JANUARY 3, 2023

The drug sector also paid tribute, with Dr Richard Torbett, CEO of the Association of the British Pharmaceutical Industry (ABPI), tweeting that Rawlins was “a great leader who has left a lasting impact on healthcare through his work at NICE, MHRA, and the NHS.”

Biobanking 52

Biobanking Medicine Drugs Production 52

XTalks

SEPTEMBER 16, 2022

levels were associated with an increased risk of EGFR mutated (EGFRm) NSCLC in England, South Korea and Taiwan, and an increased risk of mesothelioma, lung, anal, small intestine, glioblastoma (GBM), lip, oral cavity and pharynx and laryngeal carcinomas in samples from the UK Biobank. This means that a drug like an IL-1?

Research 97

Research Gene Scientist Biobanking 97

Delveinsight

MARCH 2, 2021

Chinook will have access to the NURTuRE cohort study along with other proprietary patient biobanks and Evotec’s multi-omics integration platform, and the company plans to potentially deliver targeted therapies in rare kidney diseases such as IgA nephropathy and glomerular diseases.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

Crucial Data Soutions

JUNE 28, 2021

Yet, when talking with individuals at drug sponsors with the title of “Bio Sample Management Director” or “Specimen Tracking Coordinator,” their stories are always fascinatingly consistent. Unusable samples waste money and present significant costs to drug sponsors and CROs. Current inefficient processes also cost time.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Biobanking 52

pharmaphorum

NOVEMBER 24, 2022

One will focus on the epidemiology of rare blood cancers, to try to get a handle on how prevalent they are within Europe, while another will focus on valproate – a drug for epilepsy recently thrust into the spotlight over the risks it poses to unborn children in pregnancy.

Big Data 52

Big Data Biobanking Regulation Medicine 52

The Pharma Data

OCTOBER 18, 2020

The ability to rapidly scale the production of SNG001 will allow Synairgen to meet expected clinical and commercial demand for the drug, ensuring that patients have access to this promising treatment.”. About Synairgen.

Biobanking 40

Biobanking Protein Development Manufacturing 40

Trialfacts

AUGUST 14, 2023

Men and women aged 18-65 who are diagnosed with depression Must be experiencing a current depressive episode that is lasting more than 8 weeks and less than 2 years Must currently be experiencing moderate to severe symptoms of depression Must not have a history of seizure disorders, stroke, brain tumor or any other major neurological illness that can (..)

Research 52

Research Biobanking Drugs Trials 52

Roots Analysis

DECEMBER 8, 2021

The advancements and research in the field of cellular therapies, regenerative medicine, biobanking and drug discovery have led to the demand for biopreservation media in the pharmaceutical, biotechnology and healthcare sector. The figure below portrays the various sectors / segments where media can be employed.

In-Vivo 52

In-Vivo Packaging Packaging Biobanking 52

Trialfacts

SEPTEMBER 12, 2024

Must not have a history of alcohol or drug abuse within the past 2 years. Must not have been diagnosed with cancer within the past 5 years, excluding completely treated in situ carcinoma of the cervix, and completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin or melanoma in situ.

Research 52

Research Gene Editing Biobanking Bioinformatics 52

Roots Analysis

SEPTEMBER 29, 2023

Since the 1980s, there have been significant advancements in the cryopreservation techniques used for storing stem cells, particularly hematopoietic stem cells and embryonic stem cells, which are essential in various medical applications, including regenerative medicine and biobanking.

Contamination 40

Contamination Containment Biobanking Production 40

The Pharma Data

NOVEMBER 4, 2020

The test has also been validated in CENTOGENE’s CAP / CLIA / ISO certified analytical laboratory and has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for use by authorized laboratories.

Genetics 40

Genetics In-Vitro Biobanking Containment 40

The Pharma Data

NOVEMBER 11, 2020

MULTIPLE NEW & EXTENDED DRUG DISCOVERY AND DEVELOPMENT ALLIANCES; VERY GOOD PROGRESS IN CO-OWNED PIPELINE. Multiple new and extended drug discovery and development agreements. Access to QUOD biobank to expand patient database into liver disease. m (9M 2019: € 321.4 m (9M 2019: € 308.1

Biobanking 40

Biobanking Development Containment Drugs 40

The Pharma Data

APRIL 11, 2023

In the New Drugs on the Horizon session at AACR, Bayer will present preclinical data on its novel selective diacylglycerol kinase (DGK) zeta inhibitor BAY 2965501, which is under Phase 1 clinical evaluation. These results, along with a mathematical model-informed approach have supported the currently ongoing dose expansion for BAY 2416964.

Research 40

Research Clinical Trials Clinical Trials Trials 40